Skip to main content
Lucia Masarova, MD, Oncology, Houston, TX

Lucia Masarova MD


Physician

Join to View Full Profile
  • 1515 Holcombe Blvd0428Houston, TX 77030

  • Phone+1 832-750-4211

Dr. Masarova is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Comenius University
    Comenius UniversityClass of 2007

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • TX State Medical License
    TX State Medical License 2018 - 2026
  • OK State Medical License
    OK State Medical License 2020 - 2021
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine

Clinical Trials

Publications & Presentations

Abstracts/Posters

  • Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
    Lucia Masarova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
    Lucia Masarova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly D...
    Lucia Masarova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia – Final Results of a Prospective Phase 2 Study 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Ruxolitinib plus Azacitidine Improves Survival, Bone Marrow Fibrosis in Myelofibrosis
    Ruxolitinib plus Azacitidine Improves Survival, Bone Marrow Fibrosis in MyelofibrosisNovember 13th, 2018

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: